73 related articles for article (PubMed ID: 2111137)
1. [New aspects of blood component therapy].
Dettmann C; Weippert M; Roewer J; Wilms K
Anaesthesiol Reanim; 1990; 15(2):87-93. PubMed ID: 2111137
[TBL] [Abstract][Full Text] [Related]
2. [Component therapy with cryo-poor plasma (CPP)].
Roewer J; Dettmann C
Beitr Infusionsther; 1990; 26():168-73. PubMed ID: 1703822
[TBL] [Abstract][Full Text] [Related]
3. Plasma exchange donation of cryoprecipitate after DDAVP stimulation: an alternative source of factor VIII.
McLeod BC; Scott JP
Prog Clin Biol Res; 1990; 324():189-98. PubMed ID: 2106687
[TBL] [Abstract][Full Text] [Related]
4. Comparison of albumin, colloid osmotic pressure, von Willebrand factor, and coagulation factors in canine cryopoor plasma, cryoprecipitate, and fresh frozen plasma.
Culler CA; Iazbik C; Guillaumin J
J Vet Emerg Crit Care (San Antonio); 2017 Nov; 27(6):638-644. PubMed ID: 29064153
[TBL] [Abstract][Full Text] [Related]
5. Comparison of coagulation factor XIII content and concentration in cryoprecipitate and fresh-frozen plasma.
Caudill JS; Nichols WL; Plumhoff EA; Schulte SL; Winters JL; Gastineau DA; Rodriguez V
Transfusion; 2009 Apr; 49(4):765-70. PubMed ID: 19192257
[TBL] [Abstract][Full Text] [Related]
6. [Production of factor VIII preparations and their use in the substitution therapy of hemophilia A].
Gaerisch F; Stein P
Z Gesamte Inn Med; 1982 Oct; 37(19):641-4. PubMed ID: 6817530
[TBL] [Abstract][Full Text] [Related]
7. Response of hemophilia A with bleeding to fresh dry plasma.
Krutvacho T; Chuansumrit A; Isarangkura P; Pintadit P; Hathirat P; Chiewsilp P
Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():169-73. PubMed ID: 7886565
[TBL] [Abstract][Full Text] [Related]
8. Approaches to plasma fractionation for improved recovery and the development of potentially useful clinical factors.
Johnson AJ; Mathews RW; Fulton AJ
Clin Haematol; 1984 Feb; 13(1):3-15. PubMed ID: 6426834
[TBL] [Abstract][Full Text] [Related]
9. [Recent circumstances in the supply and demand of various blood products in Japan, and appropriate use of blood components or plasma protein derivatives].
Tohyama H
Gan To Kagaku Ryoho; 1986 Oct; 13(11):3095-104. PubMed ID: 3777947
[TBL] [Abstract][Full Text] [Related]
10. Supply and need of factor VIII concentrates.
Britten A; Etzel F; Ala F; Carman C; Smit Sibinga C
Haematologia (Budap); 1983; 16(1-4):109-20. PubMed ID: 6434377
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of appropriate usage of fresh frozen plasma: Results of a regional audit in Iran.
Mirzamani N; Molana A; Poorani E
Transfus Apher Sci; 2009 Apr; 40(2):109-13. PubMed ID: 19269252
[TBL] [Abstract][Full Text] [Related]
12. The dynamics of clot formation in fresh-frozen plasma.
Lawrie AS; Cardigan RA; Williamson LM; Machin SJ; Mackie IJ
Vox Sang; 2008 May; 94(4):306-14. PubMed ID: 18266780
[TBL] [Abstract][Full Text] [Related]
13. [Possibilities to elevate the factor VIII yield].
Uteg KH; Tausendfreund K
Folia Haematol Int Mag Klin Morphol Blutforsch; 1987; 114(1):153-69. PubMed ID: 2439416
[TBL] [Abstract][Full Text] [Related]
14. Fresh frozen plasma in the pediatric pump prime: a prospective, randomized trial.
McCall MM; Blackwell MM; Smyre JT; Sistino JJ; Acsell JR; Dorman BH; Bradley SM
Ann Thorac Surg; 2004 Mar; 77(3):983-7; discussion 987. PubMed ID: 14992912
[TBL] [Abstract][Full Text] [Related]
15. [When is fresh frozen plasma indicated?].
Wegener S; Wilms K; Schlaack P; Roewer J
Anaesthesiol Reanim; 1989; 14(1):37-42. PubMed ID: 2647094
[TBL] [Abstract][Full Text] [Related]
16. Factor VIII, factor IX and fibrinogen content in cryoprecipitate, fresh plasma and cryoprecipitate-removed plasma.
Bejrachandra S; Chandanayingyong D; Visudhiphan S; Tumliang S; Kaewkamol K; Siribunrit U
Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():162-4. PubMed ID: 7886562
[TBL] [Abstract][Full Text] [Related]
17. [Factor VIII preparation produced by recombinant DNA-technology is approved in Norway].
Briseid G; Arntzen FC
Tidsskr Nor Laegeforen; 1995 Jun; 115(15):1849-51. PubMed ID: 7638835
[TBL] [Abstract][Full Text] [Related]
18. Biotechnology and the plasma fractionation industry--the impact of advances in the production of coagulation factor VIII.
Farrugia A
Australas Biotechnol; 1993; 3(1):16-20. PubMed ID: 7763537
[TBL] [Abstract][Full Text] [Related]
19. Fresh frozen plasma use in a tertiary referral hospital.
Nicholls MD; Au-Yeung D; Iannella M
J Qual Clin Pract; 1994 Jun; 14(2):77-84. PubMed ID: 8049856
[TBL] [Abstract][Full Text] [Related]
20. Von Willebrand factor multimers in virus-inactivated plasmas and F VIII concentrates.
Budde U; Drewke E
Beitr Infusionsther Transfusionsmed; 1994; 32():408-14. PubMed ID: 9422121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
